The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Fructose is a levorotatory monosaccharide and an isomer of glucose. Although fructose is a hexose (6 carbon sugar), it generally exists as a 5-member hemiketal ring (a furanose).
Synonyms:
exact_synonym:
D-arabino-hex-2-ulose
related_synonym:
D-Fru; D-arabino-Hexulose; D-laevulose; Formula=C6H12O6; Fruit sugar; Laevulose; Levulose
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate]
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate]
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA] royal jelly inhibits the reaction [Fluorides results in increased expression of BCL2 protein]
royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA] royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP3 protein]
royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; royal jelly inhibits the reaction [Fluorides results in decreased activity of CAT protein] royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein]
Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein] royal jelly results in increased activity of ESR1 protein
Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein]
royal jelly inhibits the reaction [phenylhydrazine results in decreased expression of MYC mRNA] royal jelly results in decreased expression of MYC mRNA royal jelly inhibits the reaction [Paclitaxel results in decreased expression of MYC mRNA]
browse the term
